Pharmaceuticals, Biotechnology and Life Sciences
“When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this phase 3 trial, results clearly demonstrated a significant reduction in risk of disease progression or death, ” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi.
The CHMP adopted two positive opinions recommending European Commission approval of: REVLIMID in combination with bortezomib and dexamethasone (RVd) in…
Potential to target GPRC5D in multiple myeloma patients relapsed after BCMA-targeted therapy EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical stage…
Application supported by the Phase 3 MAIA study for daratumumab in combination with lenalidomide and dexamethasone for the treatment of…
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma